Drug Profile
BIO 103 - Biophytis
Alternative Names: BIO103 - BiophytisLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Biophytis
- Class Obesity therapies
- Mechanism of Action Proto-oncogene protein c-mas-1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sarcopenia
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Sarcopenia in France (PO)
- 01 Jul 2016 Preclinical trials in Sarcopenia in France (PO)